Corrigendum to “An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis” [Diab. Res. Clin. Pract. 135 (2018) 102–110] (S0168822717314389) (10.1016/j.diabres.2017.11.002));An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis

Diabetes Research and Clinical Practice

Volumn 135, Issue , 2018, Pages 102-110

  Davidson, Mayer B ^a   Pan, Deyu ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Bladder cancer; Cardiovascular disease; Non alcoholic steatohepatitis; Pioglitazone

Indexed keywords

PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; EPIDEMIOLOGICAL DATA; HUMAN; META ANALYSIS; NONALCOHOLIC FATTY LIVER; BLADDER TUMOR; PATHOLOGY; PREVALENCE; RISK;

CARDIOVASCULAR DISEASES; COHORT STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; RISK; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 85036588517     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2018.06.014     Document Type: Erratum

References (60)

1. Ryder, R.E.J., Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit. Diabet Med 32 (2014), 305–313.
2. Lewis, J.D., Ferrara, A., Peng, T., et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34 (2011), 916–922.
3. Davidson, M.B., Pioglitazone (Actos) and bladder cancer: legal system triumphs over the evidence. J Diabetes Compl 30 (2016), 981–985.
4. Lewis, J.D., Habel, L.A., Quesenberry, C.P., et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 314 (2015), 265–277.
5. Tucorri, M., Filion, K.B., Yin, H., Platt, R.W., Azoulay, L., Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ, 352, 2016, i1541.
6. Neumann, A., Weill, A., Ricordeau, P., Fagot, J.P., Alla, F., Allemand, H., Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based study. Diabetologia 55 (2012), 1953–1962.
7. Wei, L., Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 75 (2012), 254–259.
8. Tseng, C.-H., Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 54 (2011), 2009–2015.
9. Vallarino, C., Perez, A., Fusco, G., et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fractures endpoints, using propensity score weights. Clin Drug Investig 33 (2013), 621–631.
10. Fujimoto, K., Hamamoto, Y., Honjo, S., et al. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 99 (2013), e21–e23.
11. Jin, S.-M., Song, S.O., Jung, C.H., et al. Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study. J Korean Med Sci 29 (2014), 238–242.
12. Lee, M.-Y., Hsiao, P.-J., Yang, Y.-H., Lin, K.-D., Shin, S.-J., The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese; blacker cancer and chronic kidney. PlosOne, 9, 2014, e85479.
13. Balaji, V., Seshiah, V., Ashtalakshmi, G., Ramanan, S.G., Janarthinakani, M., A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population. Indian J Endocrinol Metab 18 (2014), 425–427.
14. Levin, D., Bell, S., Sund, R., et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 58 (2015), 493–504.
15. Korhonen, P., Heintjes, M., Williams, R., et al. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. BMJ, 354, 2016, i3903.
16. Azoulay, L., Yin, H., Filin, K.B., et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ, 244, 2012, e3645.
17. Chang, C.-H., Lin, J.-W., Wu, L.-C., Lai, M.-S., Chuang, L.-M., Chan, E.A., Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 55 (2012), 1462–1472.
18. Song, S.O., Kim, K.J., Lee, B-W.L., Kang, E.S., Cha, B.S., Lee, H.C., The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone. Diabetes Metab J 36 (2012), 371–378.
19. Hsiao, F.-Y., Hsieh, P.-H., Huang, W.-F., Tsai, Y.-W., Gau, C.-S., Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case-control study. Drug Saf 36 (2013), 643–649.
20. Kuo, H.-W., Tiao, M.-M., Ho, S.-C., Yang, C.-Y., Pioglitazone use and the risk of bladder cancer. Kaohsiung J Med Sci 30 (2014), 94–97.
21. MacKenzie, T.A., Zaha, R., Smith, J., Karagas, M.R., Diabetes pharmacotherapies and bladder cancer: a Medicare epidemiologic study. Diabetes Ther 7 (2016), 61–73.
22. Bosetti, C., Rosato, V., Buniato, D., Zambon, A., La Vecchia, C., Corrao, G., Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 18 (2013), 148–156.
23. Ferwana, M., Firwana, B., Hasan, R., et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabetic Med 30 (2013), 1026–1032.
24. He S, Tang Y-H, Zhao G, Yang X, Wang D, Zhang Y. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. Tumor Biol. https://doi.org/10.1007/s13277-013-1278-x.
25. Turner, R.M., Kwok, C.S., Chen-Turner, C., Maduakor, C.A., Singh, S., Loke, Y.K., Thiazolidinediones and associated risk of bladder cancer: a systemic review and meta-analysis. Br J Clin Pharmacol 78 (2013), 258–273.
26. Pocock, S.J., Stone, G.W., The primary outcome is positive – is that good enough?. N Engl J Med 375 (2016), 971–979.
27. Cariou, B., Charbonnel, B., Staels, B., Thiazolidinediones and PPAR gamma agonists: time for a reassessment. Trends Endocrinol Metab 23 (2012), 205–215.
28. Faerch, K., Bergman, B., Perrault, L., Does insulin resistance drive the association between hyperglycemia and cardiovascular risk?. PLoS ONE, 7, 2012, e39260.
29. Mazzone, T., Meyer, P.M., Feinstein, S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 (2006), 2572–2581.
30. Nissen, S.E., Nicholls, S.J., Wolski, K., et al., for the PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (2008), 1561–1573.
31. Dormandy, J.A., Charbonnel, B., Eckland, D.J.A., et al. Secondary prevention of macrovascular events in patients with type 1 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366 (2005), 1279–1289.
32. Erdmann, E., Dormandy, J.A., Charbonnel, B., Massi-Benedetti, M., Moules, I.K., Skene AM on behalf of the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction. J Am Coll Cardiol 49 (2007), 1772–1780.
33. Wilcox, R., Bousser, M.-G., Betteridge, J., Schernthaner, G., Kupfer, S., Dormandy, J., for the PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38 (2007), 865–873.
34. Lincoff, A.M., Wolski, K., Nicholls, S.J., Nissen, S.E., Pioglitazone and risk of cardiovascular events in patient with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007), 1180–1188.
35. Tzoulaki, J., Molokhia, M., Curcin, V., et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ, 339, 2009, b4731.
36. Patel, D., Walitt, B., Lindsay, J., Wilensky, R.L., Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis. JACC Cardiovasc Interv 4 (2011), 353–360.
37. Althouse, A.D., Abbott, J.D., Sutton-Tyrrell, K., et al., for the BARI 2D STUDY GROUP. Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Care 37 (2014), 1346–1352.
38. Yang, J., Vallarino, C., Bron, M., et al. A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study. Curr Med Res Opin 30 (2014), 2223–2231.
39. Heneka, M.T., Fink, A., Doblhammer, G., Effect of pioglitazone medication on the incidence of dementia. Ann Neurol 78 (2015), 284–294.
40. Yokoyama, H., Araki, S., Kawai, K., et al., on behalf of Japan Diabetes Clinical Data Management Study Group. Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36). Diabetes Clin Res Pract 109 (2015), 485–492.
41. Tanaka, R., Yamashiro, K., Okuma, Y., et al. Effects of pioglitazone for secondary stroke prevention in patients with impaired glucose tolerance and newly diagnosed diabetes: the J-SPIRIT study. J Atheroscler Thromb 22 (2015), 1305–1316.
42. Kernan, W.N., Viscoli, C.M., Furie, K.L., et al., for the IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374 (2016), 1321–1331.
43. Tran, M.T., Navar, M.D., Davidson, M.B., Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes mellitus. Diabetes Care 29 (2006), 1395–1396.
44. U.K. Prospective Diabetes Study Group, U.K. Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 44 (1995), 1249–1258.
45. Levy, J., Atkinson, A.B., Bell, P.M., McCance, D.R., Hadden, D.R., Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabetic Med 15 (1998), 290–296.
46. McCullough, A.J., The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 8 (2004), 521–533.
47. Sanyal, A.J., Mofrad, P.S., Contos, M.J., et al. A pilot study of vitamin E versus vitamin E and pioglitazone of the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2 (2004), 1107–1115.
48. Belfort, R., Harrison, S.A., Brown, K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006), 2297–2307.
49. Aithal, G.P., Thomas, J.A., Kaye, P.V., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135 (2008), 1176–1184.
50. Sanyal, A.J., Chakasani, N., Kowdley, K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362 (2010), 1675–1685.
51. Cusi, K., Orsak, B., Bril, F., et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus. Ann Intern Med 165 (2016), 305–315.
52. European Association for the Study of the Liver (EASL) European Association for the study of Diabetes (EASD) European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016;59:1121–40.
53. Gale, E.A.M., Pioglitazone: are rumours of its death exaggerated?. Diabetic Med 32 (2015), 431–437.
54. Coughlin, S.S., Calle, E.E., Teras, L.R., Petrelli, J., Thun, M.J., Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159 (2004), 1160–1167.
55. Larrson, S.C., Orsini, N., Brismar, K., Wolk, A., Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 49 (2006), 2819–2823.
56. Fang, H., Yao, B., Yan, Y., et al. Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis of observational studies. Diabetes Tech Ther 15 (2013), 914–922.
57. https://www.google.com/webhp?sourceid=chrome-instant&ion=1&espv=2&ie=UTF-8#q=FDA+warning+of+pioglitazone+and+bladder+cancer [accessed February 10, 2017].
58. Erdmann, E., Dormandy, J.A., Charbonnel, B., et al., on behalf of the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction. J Am Coll Cardiol 49 (2007), 1772–1780.
59. Schernthaner, G., Currie, C.J., Schernthaner, G.-H., Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care 36 (2013), S155–S161.
60. Einhorn, D., Fonseca, V., Revisiting the use of pioglitazone in the treatment of type 2 diabetes. Endocr Pract 22 (2016), 1343–1346.